Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele
Young, Ross McD., Lawford, Bruce R., Barnes, Mark, Burton, Simon C., Ritchie, Terry, Ward, Warren K., & Noble, Ernest P. (2004) Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. The British Journal of Psychiatry, 185, pp. 147-151.
Background Hyperprolactinaemia induced by D2 dopamine receptor antagonist antipsychotic medication can result in significant health problems.
Aims To examine the role of DRD2 polymorphism on prolactin levels in patients treated with antipsychotic medication.
Method Antipsychotic drugs with different degrees of D2 receptor binding were given to 144 patients with schizophrenia. Serum prolactin levels were obtained and Taq1A DRD2 alleles were determined.
Results Prolactin levels increased across medication groups reflecting increasingly tight D2 receptor binding (clozapine, olanzapine, typical antipsychotics and risperidone). In the combined medication group, patients with the DRD2A1allele had 40% higher prolactin levels than patients without this allele. In patients treated with clozapine (the loosest D2 receptor binding agent), patients with the DRD2A1allele had prolactin levels twice those of patients without this allele.
Conclusions Patients with the DRD2A1 allele receiving antipsychotic medications had higher prolactin levels and were overrepresented among those with hyperprolactinaemia, suggesting greater functional D2 receptor binding in this group.
Impact and interest:
Citation counts are sourced monthly from and citation databases.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
Repository Staff Only: item control page